
Commentary|Events|September 15, 2026
- BioPharm International September October 2026
- Volume 39
- Issue 5
Architecting the Future: The Evolution of IT Landscape in the Biopharma Industry
Author(s)Partha Anbil , Anoop Sidharthan
Fact checked by: Ron Panarotti
As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.
Advertisement
Advertisement
The biopharmaceutical industry is undergoing a profound transformation driven by rapid technological advancements, shifting demographics, and stringent regulatory environments. As organizations face unprecedented pressure to accelerate drug discovery, reduce costs, and improve patient outcomes, the role of information technology (IT) has shifted fundamentally.
Related to this article

In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.

FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.

FDA declined to approve Summit Therapeutics and Akeso’s ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC. The agency said the Phase 3 HARMONi trial’s progression-free survival benefit was not enough without a significant overall survival gain.

Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.

Once-weekly self-injected gefurulimab improved daily-living scores in AChR-positive generalized myasthenia gravis in the 260-patient PREVAIL trial.

J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Advertisement
Advertisement
